In the present study, we explored the therapeutic efficacy of alpelisib, either alone or in combination with other drugs, such as the mTOR inhibitor MLN0128 or the CDK4/6 inhibitor palbociclib against GOF PIK3CA-mutated HCC both in vitro and in vivo. Here, MTOR is linked to hepatocellular carcinoma.